Protective Effect of the Total Alkaloid Extract from Bulbus Fritillariae pallidiflorae in a Mouse Model of Cigarette Smoke-Induced Chronic Obstructive Pulmonary Disease
DOI: https://doi.org/10.2147/copd.s459166
2024-06-11
International Journal of COPD
Abstract:Xiaoyu Wang, 1 Er-Bu AGA, 2 Wai Ming Tse, 3 Kathy Wai Gaun Tse, 3 Bengui Ye 1, 2 1 Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China; 2 Medical College of Tibet University, Lasa, Tibet, 850002, People's Republic of China; 3 Nin Jiom Medicine Manufactory (H.K.) Limited, Hong Kong, 999077, People's Republic of China Correspondence: Bengui Ye, West China School of Pharmacy, Sichuan University, Chengdu, 610041, People's Republic of China, Fax +86-28-85503950, Email Purpose: In recent years, the incidence of chronic obstructive pulmonary disease (COPD) has been increasing year by year, but therapeutic drugs has no breakthrough. The total alkaloid extract from Bulbus Fritillariae pallidiflorae (BFP-TA) is widely used in treating lung diseases. Therefore, this study aimed to investigate the protective effect and mechanism of BFP-TA in COPD mice. Methods: BFP-TA was prepared by macroporous adsorbent resin, and the material basis of BFP-TA was analyzed by HPLC-ELSD and UHPLC-MS/MS. Then, the COPD mouse model was induced by cigarette smoke (CS) for 12 weeks, administered at weeks 9– 12. Subsequently, the body weight, lung-body ratio, pulmonary function, histopathology, and the levels of pro-inflammatory cytokines, matrix metalloproteinases (MMPs) and oxidative stress markers in the serum of mice were determined. The expressions of related protein of EMT and MAPK signaling pathways in the lung tissues of mice were detected by Western blot. Results: The alkaloid relative content of BFP-TA is 64.28%, and nine alkaloids in BFP-TA were identified and quantified by UHPLC-MS/MS. Subsequently, the animal experiment showed that BFP-TA could improve pulmonary function, and alleviate inflammatory cell infiltration, pulmonary emphysema, and collagen fiber deposition in the lung of COPD mice. Furthermore, BFP-TA could decrease the levels of pro-inflammatory cytokines (TNF-α, IL-6 and IL-1β), MMPs (MMP-9 and MMP-12) and MDA, while increase the levels of TIMP-1 and SOD. Moreover, BFP-TA could decrease the protein expressions of collagen I, vimentin, α-SMA, MMP-9, MMP-9/TIMP-1, Bax, p-JNK/JNK, p-P38/P38, and p-ERK/ERK, while increase the level of E-cadherin. Conclusion: This study is the first to demonstrate the protective effect of BFP-TA in CS-induced COPD mouse model. Furthermore, BFP-TA may improve airway remodeling by inhibiting the EMT process and potentially exert anti-inflammatory effect by inhibiting the MAPK signaling pathway. Keywords: Bulbus Fritillariae pallidiflorae , total alkaloid, COPD, EMT, MAPK Chronic obstructive pulmonary disease (COPD) is a disease characterized by restricted and incompletely reversible airflow, inflammation of the lungs, and the destruction of emphysema. 1 There are two main phenotypes: the airway phenotype, characterized by chronic obstructive bronchitis; and the emphysematous phenotype, characterized by reduced gas exchange area and exercise capacity. 2 Based on a report released by the World Health Organization in 2020, 3 COPD has become the third leading cause of death in the world, and the fatality rate is increasing every year. COPD is usually caused by regular exposure to smoking, toxic gases, dust particles, etc., 4,5 among which smoking is recognized as the most important factor contributing to COPD and irreversible airflow limitations. The pathogenesis of COPD is complex, currently, the recognized pathogenic mechanisms include chronic inflammation, oxidative stress, protease/anti-protease imbalance, airway remodeling, apoptosis, decreased immunity, etc., and the pathogenesis of COPD is caused by combination of multiple mechanisms. 6–8 Although basic research on COPD has many achievements, the pathogenesis of COPD has not been fully elucidated, and there has no breakthrough in therapeutic drugs. Therapeutic interventions for COPD focus on improving lung function, symptoms, quality of life, and reducing disease progression rather than the risk of death. 9 Currently, bronchodilators (such as β2 agonists, anticholinergics, and theophyllines), glucocorticoids, and phosphodiesterase inhibitors are often used in the clinical pharmacotherapy of COPD. 10–12 They mainly focus on improving symptoms, reducing complications, and regulating lung function, and are mostly used in combination to control symptoms. However, glucocorticoids, β2 agonists, and anticholinergics have obvio -Abstract Truncated-
respiratory system